Search RTI Surgical

RTI Surgical Issues Presentation Outlining Why Stockholders Should Vote for the Company's Director Nominees on the White Proxy Card

May 6, 2016

Wendy Crites Wacker, APR
Vice President, Global Communications
wwacker@rtix.com
386.418.8888

Bill Fiske
Georgeson
bfiske@georgeson.com
212.440.9128

INDEPENDENT NOMINATING AND GOVERNANCE COMMITTEE SELECTED A HIGHLY QUALIFIED SLATE OF DIRECTOR NOMINEES AFTER A THOROUGH EVALUATION

KRENSAVAGE REJECTS REASONABLE SETTLEMENT OFFER THAT INCLUDED APPOINTMENT OF ONE OF KRENSAVAGE’S NOMINEES

ALACHUA, Fla. (May 6, 2016) – RTI Surgical Inc. (“RTI” or “the Company”) (Nasdaq: RTIX), a global surgical implant company, today issued a presentation titled “RTI Surgical: Creating a Stronger Governance Structure and Building Long-Term Stockholder Value.” The presentation outlines why RTI stockholders should vote the WHITE proxy card FOR the election of Peter F. Gearen, Brian K. Hutchison, Thomas A. McEachin, Jonathon M. Singer, Paul G. Thomas, Nicholas J. Valeriani and Shirley A. Weis, RTI’s highly qualified director nominees, at the Company’s upcoming annual meeting of stockholders on May 26, 2016. Messrs. Gearen, Hutchison, and McEachin and Ms. Weis are existing directors.

The presentation can be found at www.rtix.com/en_us/investors/electronic-ir-kit.

Highlights of the presentation include:

• After careful evaluation, the independent nominating and governance committee unanimously concluded that RTI’s director nominees are the better leadership team to direct management and the business and increase long-term stockholder value. The nominating and governance committee concluded that Krensavage Partners, LP’s (“Krensavage”) nominees are less qualified than RTI's nominees to be directors of RTI.
• RTI is committed to the right governance framework to increase stockholder value and has refreshed its board in an attempt to ensure that the directors will help the Company respond to a changing industry and regulatory landscape. If all of RTI’s director candidates, including the three new ones, are elected to the RTI board at the upcoming annual meeting, seven of RTI’s nine directors will have terms of less than three years.
• Krensavage rejected RTI’s reasonable settlement offer that included the appointment of one of Krensavage’s nominees. Krensavage prefers to pursue a proxy contest at this time. RTI has consistently engaged with Krensavage in an effort to avoid a potentially long and expensive proxy contest.
• RTI is making significant progress executing its plan to grow revenues and increase margins. Strategic steps are delivering stronger financial performance, including 2015 year-over-year growth in revenues of 7.4% (9% on a constant currency basis), EBITDA of 36.3% and adjusted net income per fully diluted common share of 109%.

RTI Corrects Krensavage’s Misleading and Factually Inaccurate Statements

The presentation also corrects the misleading and factually inaccurate statements that have been made by Krensavage in its public communications:

• The Krensavage nominee, John Watts, was interviewed by RTI’s nominating and governance committee as part of its evaluation process. During the telephonic interview, Mr. Watts stated that, in his view, his skills were duplicative with those of current board member Ms. Weis. Krensavage subsequently notified the Company that it had decided to replace Mr. Watts with Darren Lehrich.
• RTI's total insider ownership stake is greater than the mean ownership stake of 22.5% for RTI's comparables as chosen by Krensavage. The RTI board includes significant stockholder representation with two directors associated with the Company’s largest investor, Water Street Healthcare Partners.
• RTI’s R&D and SG&A expenses as a percentage of sales are below the industry mean and median. Krensavage’s comments on expenses are misleading because they focus on absolute dollar amounts and ignores normal sector spending levels.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.

Important Additional Information

RTI Surgical filed a proxy statement with the SEC in connection with the solicitation of proxies for its 2016 annual meeting of shareholders. Shareholders are strongly advised to read RTI’s 2016 proxy statement and the accompanying WHITE proxy card because they contain important information. Shareholders are able to obtain copies of RTI’s 2016 proxy statement, any amendments or supplements to the proxy statement and other relevant solicitation materials filed by RTI with the SEC in connection with its 2016 annual meeting of shareholders free of charge at the SEC’s website at www.sec.gov, on the company’s website at www.rtix.com, or by writing to our Corporate Secretary at our principal office at 11621 Research Circle, Alachua, Florida 32615. RTI, its directors, and its executive officers may be deemed participants in the solicitation of proxies from shareholders in connection with its 2016 annual meeting of shareholders. Information concerning persons who may be considered participants in the solicitation of RTI’s shareholders under the rules of the SEC is set forth in public filings filed by RTI with the SEC and is set forth in its proxy statement relating to its 2016 annual meeting of shareholders.

###